Insider trading research with Taiwanese vaccine makers reveals broader issues
bernardblack, 02 July 2021
A survey of insider trading with Taiwan’s Covid-19 vaccine maker raised concerns about Taiwan’s fiscal oversight and involved President Tsai Ing-wen’s administration.
The Taipei-based Shilin District prosecutor’s office said Medigen Vaccine Biologics Corporation after the company’s stake jumped more than 20% in the days before announcing positive results for a phase II vaccine trial in June. He told the Financial Times that he was investigating. The prosecution refused to reveal the details of the investigation.
Tsai rejected accusations from political opponents in a television speech last month that the government blocked the import of vaccines to boost Medigen’s stock price.
Investigation opens another front where Tsai’s political rivals can attack the president as they try to fend off external pressure from China
Only 8.2% of Taiwan’s population has received the first jab, and the government has agreed to buy 5 million vaccines from Medigen to solve the shortage that Taipei is partially blaming China. Block the purchase of foreign-made doses..
